Global control of content with seamless information sharing is an important key factor for innovative and international operating Life Sciences Companies. Therefore, CSL decided to introduce the EMC Life Sciences Solution Suite with its business area-specific modules, which ensures consistent access, compliance and security while improving business productivity and efficiency. “A big milestone of this project is the migration of our content to D2. fme is an important partner in the field of content migrations for CSL offered as a global service. We used the fme migration product when we moved to D2,” explains Johannes Lichtenfels, Senior Manager Business Solutions Document Management of CSL.
Currently, CSL Behring is using the enterprise content management solution EMC Documentum including Webtop and D2 as interface. The D2 layer is the technical basis of the EMC Life Science Solution Suite, which is specifically developed for supporting business processes such as quality assurance, research and development etc. With the help of fme’s migration experts and their software migration-center, CSL was migrating content from Documentum to the D2 application. “We are looking back on almost 10 years of good cooperation between CSL and fme and we are very happy to have served CSL internationally again with this large migration project,” says Florian Piaszyk, Director fme Products.
migration-center is a full function, out-of-the-box software solution, fully documented, easy to deploy, with an excellent graphical user interface. The product has been EMC-certified for ten years and is able to carry out highly automated, large volume document migrations without interrupting any of the normal business operations.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs nearly 20,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit www.cslbehring.com